PROF
Profound Medical Corp.NASDAQHealthcare$6.43-1.53%ClosedMarket Cap: $194.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.20
P/S
10.73
EV/EBITDA
-2.88
DCF Value
$-22.01
FCF Yield
-20.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.2%
Operating Margin
-239.5%
Net Margin
-248.5%
ROE
-85.7%
ROA
-23.7%
ROIC
-23.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $6.1M | 0.1% | $-8.2M | $-8.3M | $-0.27 | — |
| FY 2025 | $16.1M | 70.8% | $-42.0M | $42.3M | $1.41 | — |
| Q3 2025 | $5.2M | 74.3% | $-8.8M | $-7.9M | $-0.37 | — |
| Q2 2025 | $2.2M | 73.2% | $-13.8M | $-15.7M | $-0.52 | — |
| Q1 2025 | $2.6M | 70.7% | $-11.2M | $-10.7M | $-0.36 | — |
| Q4 2024 | $5.3M | 68.1% | $-82.5M | $-7.7M | $-0.19 | — |
| FY 2024 | $10.2M | 65.9% | $-31.5M | $-26.5M | $-1.07 | — |
| Q3 2024 | $3.8M | 63.8% | $12.2M | $-12.7M | $-0.38 | — |
| Q2 2024 | $2.2M | 63.6% | $-7.8M | $-6.9M | $-0.28 | — |
| Q1 2024 | $1.4M | 60.2% | $-7.9M | $-6.6M | $-0.26 | — |
| Q4 2023 | $2.7M | 49.2% | $-64.2M | $-11.5M | $-0.42 | — |
| FY 2023 | $7.2M | 60.9% | $-28.6M | $-28.6M | $-1.35 | — |